[HTML][HTML] SARS-CoV-2 rebound with and without use of COVID-19 oral antivirals
DJ Smith - MMWR. Morbidity and Mortality Weekly Report, 2023 - cdc.gov
Early treatment with a first-line therapy (nirmatrelvir/ritonavir [Paxlovid] or remdesivir) or
second-line therapy (molnupiravir) prevents hospitalization and death among patients with …
second-line therapy (molnupiravir) prevents hospitalization and death among patients with …
[HTML][HTML] Evaluation of SARS-CoV-2 RNA rebound after nirmatrelvir/ritonavir treatment in randomized, double-blind, placebo-controlled trials—United States and …
PR Harrington - MMWR. Morbidity and Mortality Weekly Report, 2023 - cdc.gov
Rebound of SARS-CoV-2 shedding or COVID-19 signs and symptoms has been described
after treatment with nirmatrelvir/ritonavir (Paxlovid). The direct association of …
after treatment with nirmatrelvir/ritonavir (Paxlovid). The direct association of …
The SARS-CoV-2 infection rebound among patients receiving antiviral agents, convalescent plasma, or no treatment: a systematic review with meta-analysis: SARS …
I Pati, M Cruciani, F Masiello, V Piccinini… - Blood …, 2024 - bloodtransfusion.it
Background-There is some evidence showing rebound of COVID-19 infections in patients
treated with nirmatrelvir-ritonavir between 2 and 8 days following cessation of the antiviral …
treated with nirmatrelvir-ritonavir between 2 and 8 days following cessation of the antiviral …
Repurposing Revisited: Exploring the Role of Metformin for Treatment of Coronavirus Disease 2019
MJ Siedner, PE Sax - Clinical Infectious Diseases, 2024 - academic.oup.com
Approximately 4 years into the coronavirus disease 2019 (COVID-19) pandemic, available
treatment options for outpatients have a mixed track record. The most notable success is …
treatment options for outpatients have a mixed track record. The most notable success is …
Combined Protection of Vaccination and Nirmatrelvir-Ritonavir Against Hospitalization in Adults With Coronavirus Disease 2019
MM Shah, B Joyce, ID Plumb… - Clinical Infectious …, 2024 - academic.oup.com
Among adults at risk for severe coronavirus disease 2019 (COVID-19), the lowest
hospitalization rate was among those who received nirmatrelvir-ritonavir after 3 or more …
hospitalization rate was among those who received nirmatrelvir-ritonavir after 3 or more …
COVID-19 clinical rebound after treatment with nirmatrelvir/ritonavir
D Camp, M Caputo, FM Echevarria… - Research …, 2024 - researchsquare.com
Abstract Background: Nirmatrelvir/ritonavir (NM/r) is a safe and effective oral antiviral
therapeutic used for treatment of mild-to-moderate COVID-19. Case reports described a …
therapeutic used for treatment of mild-to-moderate COVID-19. Case reports described a …
[PDF][PDF] Combined Protection of Vaccination and Nirmatrelvir-Ritonavir Against Hospitalization in Adults With Coronavirus Disease 2019
MM Shah, B Joyce, ID Plumb, S Sahakian… - scholar.archive.org
Among adults at risk for severe coronavirus disease 2019 (COVID-19), the lowest
hospitalization rate was among those who received nirmatrelvir-ritonavir after 3 or more …
hospitalization rate was among those who received nirmatrelvir-ritonavir after 3 or more …